TrialClinical pharmacokinetics2025
Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.
Celine Konecki et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it